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Background: Cardiovascular diseases contribute substantially to the poor health and reduced life expectancy of
Indigenous Australians. Heart failure is a common, disabling, progressive and costly complication of these disorders.
The epidemiology of heart failure and the adequacy of relevant health service provision in Indigenous Australians
are not well delineated.
Methods: A systematic search of the electronic databases PubMed, Embase, Web of Science, Cinahl Plus, Informit
and Google Scholar was undertaken in April 2012 for peer-reviewed journal articles relevant to the topic of heart
failure in Indigenous Australians. Additionally, a website search was done to identify other pertinent publications,
particularly government reports.
Results: There was a paucity of relevant peer-reviewed research, and government reports dominated the results.
Ten journal articles, 1 published conference abstract and 10 reports were eligible for inclusion. Indigenous
Australians reportedly have higher morbidity and mortality from heart failure than their non-Indigenous
counterparts (age-standardised prevalence ratio 1.7; age-standardised hospital separation ratio ≥3; crude per capita
hospital expenditure ratio 1.58; age-adjusted mortality ratio >2). Despite the evident disproportionate burden of
heart failure in Indigenous Australians, the accuracy of estimation from administrative data is limited by poor
indigenous identification, inadequate case ascertainment and exclusion of younger subjects from mortality statistics.
A recent journal article specifically documented a high prevalence of heart failure in Central Australian Aboriginal
adults (5.3%), noting frequent undiagnosed disease. One study examined barriers to health service provision for
Indigenous Australians in the context of heart failure.
Conclusions: Despite the shortcomings of available published data, it is clear that Indigenous Australians have an
excess burden of heart failure. Emerging data suggest that undiagnosed cases may be common in this population.
In order to optimise management and to inform policy, high quality research on heart failure in Indigenous
Australians is required to delineate accurate epidemiological indicators and to appraise health service provision.
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Heart diseaseBackground
Indigenous Australians are known to suffer poorer health
and lower life expectancy than their non-Indigenous
counterparts. This life expectancy gap is attributable
substantially to chronic conditions such as cardiovascular
disease [1].
Heart failure (HF; synonyms: congestive heart failure,
cardiac failure) is a ‘complex and lethal clinical syndrome’* Correspondence: john.woods@uwa.edu.au
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reproduction in any medium, provided the or[2] in which the heart is unable to provide blood flow
adequate for the body’s metabolic needs [3]. Although HF
is traditionally conceptualised as an impairment of the
heart’s ability to pump sufficient blood into the circulation
during systole, it is now recognised that left ventricular
ejection fraction, a measure of systolic function, is pre-
served in many cases [4], and that this pathophysiological
heterogeneity of HF may be influenced by the spectrum of
underlying causes [5].
The antecedents of HF, especially hypertension [6,7] and
coronary heart disease including myocardial infarctionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genous Australians. Importantly, these conditions tend to
become manifest at a younger age than among non-
Indigenous persons, resulting in a much greater burden of
disease, and contributing to greater levels of disability in
Indigenous populations [1]. Renal disease, which clusters
with features of the metabolic syndrome as a predictor of
cardiac illnesses, is prevalent at extremely high levels in
some Indigenous populations [10,11]. Diabetes, frequently
associated with this cluster of cardiovascular conditions,
also occurs at a much higher rate among indigenous
Australians [12], and may independently predispose to HF
[13]. Moreover, Indigenous Australians are known to suffer
an exceptionally high incidence of rheumatic fever, with the
potential sequelae of chronic rheumatic heart disease and
HF [14].
Regardless of the underlying cause, HF is an important
cardiovascular problem in its own right, being associated
with substantial disability, impaired quality of life and
diminished survival [15]. Further, timely identification of
HF with institution of evidence-based interventions
diminishes symptoms and potentially prolongs life [16,17].
However, the epidemiological indicators of HF among
Indigenous Australians are poorly delineated. Although
administrative data on HF in the Australian population
are published regularly, particularly by the Australian
Institute of Health and Welfare (AIHW), the accuracy of
such administrative data, and the validity of epidemiological
comparisons between Indigenous and non-Indigenous
populations derived from these data are fraught, doubly in
this instance given that there are caveats on both ascertain-
ment of HF [18,19] and identification of Indigenous status
[20]. Further, administrative data are generally not person-
based, for example, re-admissions of the same patient can-
not be distinguished [21]. Consequently, quality research
specifically addressing HF in the Indigenous population
is needed to verify indicator measures derived from
administrative data.
Personal and psychosocial perspectives, based on quali-
tative research, are also important for understanding the
effects of HF in the Indigenous population. Such informa-
tion is a valuable adjunct to quantitative data in estimating
the impact of the disease and to inform planning.
This review specifically explores publicly available
information on HF in the Australian Indigenous population
through: (1) a systematic search of the peer-reviewed litera-
ture and (2) a review of reports published on this topic
based on analyses of administrative data by Australian
federal and state/territory governments.
Methods
Search of peer-reviewed journal databases
A systematic search of the electronic databases PubMed,
Embase, Scopus, Web of Science, Cinahl Plus, Informit andGoogle Scholar was undertaken, using search terms that
comprised: (i) subject headings, specified by the respective
databases related to heart failure or to Indigenous status
(for example Medical Subject Heading [MeSH] in
PubMed), and (ii) other synonyms for HF and Indigenous
status, either listed by the electronic databases or generated
by the authors. The search retrieved articles containing one
or more terms relevant to both heart failure and Australian
Indigenous (Aboriginal or Torres Strait Islander) status. A
full list of search terms used is provided below (Additional
file 1: Table S1). The search was restricted to articles pub-
lished from 1990 onwards and to English language publi-
cations. Duplicates were identified and removed by
automated search and manual scrutiny of the remaining
list of citations.
The search strategy was modified for Google Scholar.
Given the limited Boolean syntactical capacity of the
Google Scholar search engine [22], a search with fewer,
more general search terms was done. This retrieved a large
number of citations (about 3000) including articles not else-
where identified that contained ‘heart failure’ as a phrase in
the full text, even if this was not present in the title,
abstracts or keywords. The first 50 citations were screened
manually for relevance and to ensure non-duplication of
citations from other databases.Search of websites for relevant reports
The Australian Government and state/territory Department
of Health websites were searched from within the Google
interface or using departmental website internal search
engines for documents with the terms ‘Aboriginal or Indi-
genous or heart failure or cardiac failure’. The Australian
Institute of Health and Welfare (AIHW) website was in-
dependently searched for relevant articles as was the
Australian Indigenous Health InfoNet website, a clear-
inghouse specifically devoted to reports and informa-
tion pertaining to health of Indigenous Australians.
References lists from articles and reports included in
the search were also checked for relevant publications.Inclusion criteria
Studies were considered for inclusion if they dealt with the
Australian Indigenous population and included post-1990
data or qualitative evidence on one or more pre-defined
heart failure-related issues related to (1) prevalence or inci-
dence, either population-based or within clinical groups or
clinical service settings (such as acute coronary syndrome
cohorts); (2) aetiology, risk factors or clinical presentation
and pathophysiology; (3) co-morbidities; (4) mortality &
survival; (5) quality of life; (6) therapeutic interventions; (7)
health service utilisation (including medication adherence,
primary care attendances, hospitalisations, cardiac rehabili-
tation); (8) health service delivery issues (including needs,
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and care.
One author (JW) screened all of the references (n=127)
by title and abstract. A large number of references were
deemed not relevant on the basis of this initial screening.
The criteria for exclusion on this preliminary screening
(Table 1) were checked and accepted by other authors (JK
and ST). The remaining references (n = 51) were reviewed
jointly by two authors (JW and JK).
Although at the outset it was not proposed to include
conference abstracts, in view of the scarcity of published
information, one abstract was ultimately included to
reflect work/research as yet unpublished.
Results
Of 145 journal articles or conferences abstracts identi-
fied (Figure 1), 94 were excluded on the basis of preli-
minary screening (Table 1). Of the 51 remaining papers
reviewed by two authors, 9 were eligible for inclusion
with a further two eligible articles published while the
manuscript was under review (Table 2). Ten reports
were also included (Table 3).
Prevalence or incidence, either population-based or
within clinical groups or clinical service settings (such as
acute coronary syndrome cohorts)
Peer-reviewed studies
There was only one peer-reviewed, population-based study
of HF prevalence in the Australian Indigenous population,
and none of incidence rates. McGrady and colleagues
reported on the “Heart of the Heart” study, in which
volunteering adult Aboriginal participants from 6 Central
Australian communities were enrolled in 2008–9 for a
comprehensive cardiac assessment which included a
researcher-administered structured questionnaire (medical
history, drugs, smoking, alcohol intake and HF symp-
toms), medical record review, anthropomorphic measures
(waist circumference, height and weight), blood pressure,
cardiac and lung auscultation and fluid status assessmentTable 1 Criteria for Exclusion based on Title/Abstract
Alone
N
Indigenous other than Australian Aborigines or Torres Strait
Islander peoples:
1. Non-Australian Indigenous human subjects 59
2. ‘Indigenous’ botanicals 11
3. Other non-anthropological meanings of ‘indigenous’
(e.g., as synonym for ‘intrinsic’)
10
Review articles – no original data 6
Duplicate data 2
Case report data only 6
TOTAL 94by a study cardiologist, biochemistry (for assessment of
renal function, random non-fasting blood glucose level,
glycosylated haemoglobin (HbA1c) and B-type natriuretic
peptide (BNP) [25]. The prevalence of HF was 5.3% (95%CI
3.2-7.5%), with asymptomatic left ventricular dysfunction
present in a further 13%. In 65% of those with HF detected,
the disorder had not been previously diagnosed. The inter-
pretability of the reported prevalence estimate in this study
is limited by the absence of a non-Indigenous comparison
group and uncertain representativeness of the participants
in relation to the Central Australian Aboriginal community,
although the age profile and prevalence of comorbidities
are similar to findings of other whole-of-community med-
ical record reviews.
Two retrospective cohort studies, both based on adminis-
trative linked data, reported the frequency of several co-
morbidities, including HF, among Indigenous subjects with
coronary heart disease. In a study of patients admitted to
Queensland public hospitals with acute myocardial infarc-
tion MI [23], Indigenous subjects had a higher prevalence
of HF as a concurrent comorbidity (age-adjusted risk-ratio
1.67; 95% CI 1.35-2.00). In another study of 28-day survi-
vors of first-ever MI in Western Australia, current or
5-year history of HF was more common among Indigenous
subjects than their non-Indigenous counterparts (males:
17% versus 13%; p=0.018; females: 31% versus 22%;
p=0.003), even though the median age of Indigenous sub-
jects was 13–14 years lower [24].Government reports
The periodic National Aboriginal and Torres Strait
Islander Health Survey (NATSIHS) provides data on self-
reported health problems. In the 2004–05 NATSIHS,
information was collected from a sample of 10,400 per-
sons, constituting about 1 in 45 of the total Indigenous
population [33]. Comparator non-Indigenous data were
obtained from the 2004–05 National Health Survey
(n=approximately 25,900), intended to be representative
of Australian households (but excluding subjects from
Very Remote locations, unlike the NATSIHS). Survey
samples included only the usual residents of private dwel-
lings. The presence of ‘oedema’ was considered synony-
mous with HF in the self-reported data. In this survey, the
overall prevalence of self-reported HF or oedema among
Indigenous Australians was 1.0%, with age-standardised
prevalence estimates of 17.4/1000 (95% CI 6.3-28.5) in
Indigenous males and 28.8/1000 (95% CI 17.0-40.7) in
Indigenous females. The precision of these estimates is
likely to be poor, with a relative standard error of 25-50%
reported for the male estimate. The Indigenous to non-
Indigenous age-standardised prevalence ratio was 1.7 over-
all (males 1.9; females 1.6, not statistically significant for
either sex, but significant for both sexes combined) [33].








11 articles included from literature search
10 Government reports
Total N=21 publications included in review
51 abstracts co-reviewed by 2 authors
Full text reviewed if unclear




Excluded if clearly not relevant,
based on title/abstract    N=94
Google Scholar N=18
N=145 titles/abstracts reviewed for 
relevance
Papers published while under 
review N=2
Figure 1 Flowchart.
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pathophysiology
In the recent report by McGrady and colleagues, the key
risk factors associated with HF in a Central Australian
Aboriginal population were coronary heart disease, hyper-
tension, diabetes mellitus, obesity, and a history of acute
rheumatic fever or rheumatic heart disease (Table 2).
Diabetes, hypertension and obesity (individually or in com-
bination) were contributing factors in 48% of HF cases and
79% of those with asymptomatic left ventricular dysfunc-
tion, while 9% and 13% of these cases respectively had no
clearly identified contributory risk factor [25]. Although the
likely antecedents of HF in the Indigenous population
(particularly coronary and rheumatic heart disease) are well
discussed in the literature, HF was otherwise onlymentioned incidentally in several studies of Indigenous
Australians as a fatal complication (see below) of coronary
[28] or rheumatic heart disease [29].
No studies quantified the contribution of pulmonary
disease to HF in Indigenous Australians, or linked chronic
obstructive pulmonary disease with HF in this population.
However, co-morbid HF was reported in one retrospective
cohort study of the role of human T-lymphotropic virus-1
(HTLV-1) infection in determining outcomes among
Central Australian Indigenous adult subjects who had been
hospitalised with bronchiectasis (n=89) [26]. HF was
present in 22 patients and cor pulmonale was diagnosed in
11. HTLV-1 seropositivity was associated with worse
outcomes. In addition to an increased likelihood of adverse
radiographic indicators of pulmonary disease and increased
Table 2 Peer-reviewed journals
Author(s)/year
Publication Type
Study Population and Time Period Methods Key finding(s) pertinent to heart failure Validity and generalisability issues
(including Indigenous identification)
1. Prevalence or incidence, either population-based or within clinical groups or clinical service settings
Coory et al. (2005) [23]
Original article
Queensland patients hospitalised
with MI in public sector N=14683,
Indigenous=558
Design: Retrospective
cohort study (I year
follow-up)
HF more commonly a concurrent co-morbidity
among Indigenous than non-Indigenous identified
patients (age-adjusted RR 1.64; CI 1.35-2.00)
• HF one of several co-morbidities assessed;
not an endpoint of study.
Data source: linked
hospital data
• No adjustment for administrative under-
identification of Indigenous status





All WA patients hospitalised with
non-fatal first-ever MI N=7480,
Indigenous=532
Design: retrospective




HF more commonly a concurrent or past co-
morbidity among Indigenous than non-Indigenou
identified patients (males: 17% vs. 13%; p=0.018;
females: 31% vs. 22%; p=0.003)
• HF one of several co-morbidities assessed;
not an endpoint of study.
• Indigenous status based on ever-
identification in hospital or death records
Period: Admitted Jan 2000-Dec 2004 Outcome: recurrent
MI/CVD death
• Crude HF prevalence, no age adjustment
thus underestimate of disparity
McGrady et al. (2012) [25]
Original Article
Consenting Aboriginal adults (>18
years) residing in one of six Central
Australian communities, (Alice
Springs, Town Camp or remote)
N=436 (mean age 44 years)
Design: cross-sectional
clinical survey
HF detected in 5.3% (CI 3.2-7.5%); 65% of these no
pre-existing HF diagnosis.
ALVD present in a further 13% (CI 9.4-15.7%)
• Population-based study designed
specifically to assess epidemiology of HF and
risk factors among Central Australian





• Volunteer participants – representativeness
uncertain
Period: Assessment May 2008 -
Nov 2009
Outcome: presence of HF
or ALVD
• No non-Indigenous comparison group
2. Aetiology, risk factors, clinical presentation and pathophysiology
Einsiedel et al. (2012)
[26] Original article
Indigenous adults (n=89) admitted
to a single general hospital with






HF (35% versus 11%; p=0.013) more common in
human HTLV-1 seropositive than HTLV-1
seronegative subjects.
• HF one of several complications assessed
• Indigenous status identified from medical
records
• Comparison not age-adjusted,
• however mean age essentially identical in
both groups.
• Population restricted
Period: Jan 2000-Dec 2006 Outcome: bronchiectasis
outcomes





symptomatic HF referred to a heart




57% had normal systolic function • Indigenous status identification not explicit
Data source: Hospital and
echocardiograph records
• No non-Indigenous comparison
group





















Table 2 Peer-reviewed journals (Continued)
McGrady et al. (2012)
[25] Original article
Aboriginal adult volunteers (>18
years) residing in six Central
Australian communities, N=436
(mean age 44 years)
Design: cross-sectional
clinical survey
Age & sex-adjusted odds ratio for HF:
CAD (9.6, p<0.001)
• Population-based study designed
specifically to assess epidemiology of HF and
risk factors among Central Australian







Period: Assessment May 2008 -
Nov 2009
Outcome: presence of HF
or ALVD
Obesity (2.9, p=0.022) • Volunteer participants – representativeness
uncertain
RHD history (5.6, p=0.001) 39% of HF cases had
preserved ejection fraction
• No non-Indigenous comparison group
3. Co-morbidities
McGrady et al. (2012)
[25] Original Article
Aboriginal adult volunteers (>18
years) from six Central Australian




Crude prevalence in HF cases: Diabetes 78%
Hypertension 78% CAD 39% ARF/RHD 26%
• Population-based study designed
specifically to assess epidemiology of HF and
risk factors among Central Australian





Period: Assessment May 2008 -
Nov 2009
Outcome: presence of HF
or ALVD
• Volunteer participants – representativeness
uncertain
• No non-Indigenous comparison group
4. Mortality & survival
Brown (2010) [28]
Original article
Patients admitted to two NT




Frequency of death attributed to HF was similar in
both Indigenous (approx. 2.2%) and non-Indigenous
(approx. 2.0%).
• Indigenous identification is relatively good
in NT administrative records; no additional
effort to improve identification




Period: Admissions Jan 2001-Dec
2002; 2 year follow-up
Outcome: All-cause and
CVD deaths
Carapetis et al. (1999)
[29] Original article
80 consecutive patients (70
Indigenous) with surgical valve
replacement for RHD
Design: Cohort study 29 late deaths, 27 attributed to RHD, 12 of these
were HF deaths (plus 1 due to ‘HF and pneumonia’)
• No comparison group.
Data source: Hospital
records
• Long calendar period of case acquisition
(1964–1996) limits contemporary
interpretability of prognosis.
Period: Surgery 1964–1996; all

























See Part 1. above See Part 1. above HF as a co-morbidity independently associated with
about double the risk of composite outcome
(recurrent AMI or death) in both Indigenous and
non-Indigenous subjects
• HF was one of a number of demographic
and co-morbidity variables in the model




7. Health service utilisation (including medication adherence, outpatient attendances, hospitalisations, cardiac rehabilitation)
Bolton et al. (2011) [30]
Conference abstract




2 of 68 patients (3%) referred to an inner-suburban
AMS-controlled cardiology clinic had HF.
• Encounter proportions without comparison
group difficult to interpret
Data source: Clinic records
Period: July 2009-2011 Outcome: Attendance,
encounter proportions
• Uncertain generalisability to Australian
Indigenous population.
Thomas et al. (1998) [31]
Original article
Primary care (AHW and/or doctor)




Proportion of encounters involving HF: 3.4% (95%
CI 1.9-4.9) compared with 1.6% in national
comparison data (AMTS)
• Comparison of encounter proportions
difficult to interpret
Data source: Clinic records • Uncertain generalisability to Australian
Indigenous population.
Period: 2 separate study weeks 6
months apart: in Darwin’s wet




8. Health service delivery issues (including needs, access and barriers)
Clark et al. (2007) [32]
Original article




Highest prevalence of HF in areas with people aged
>65 years and higher proportions of Indigenous
people.
• No direct measure of HF prevalence (based
on international prevalence data).
Data source: Census data,
international prevalence
estimates




• Indigenous:non-Indigenous HF prevalence
ratio estimated from AIHW HF mortality
data.
Outcome: Indirect measure
of access to CR services
Geographical inequity in provision of HF specialist
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Aspin et al. (2012) [32]
Original article
19 Indigenous subjects (age range
34–70) from Western Sydney or








Negative influences were poor access to culturally
appropriate health services, dislocation from cultural
support systems, racism, poor communication with
health professionals and economic hardship Positive
influences were strength drawn from being part of
the Aboriginal community, regular ongoing access to
primary care and a supportive family network
• Findings not specific to HF but reflect issues
related to chronic disease care of HF
prevalence (based on international prevalence
data).
Data source: n.a. • Indigenous population distribution derived
from Census data.
Period: Jan 2004-Dec 2005 Outcome: Description of
barriers and facilitators of
access to care and support
• Indigenous: non-Indigenous HF prevalence
ratio estimated from AIHW HF mortality
data.
9. Costs related to HF diagnosis and care
Nil
ACS: acute coronary syndrome.
AHW: Aboriginal Health Worker.
AIHW: Australian Institute of Health and Welfare.
ALVD: Asymptomatic left ventricular dysfunction.
AMS: Aboriginal Medical Service.
AMTS: Australian Morbidity and Treatment Survey.
CAD: coronary artery disease.
CI: 95% confidence interval.






HTLV-1: Human T-lymphotropic virus type 1.
MI: myocardial infarction.
OR: odds ratio.






















Author(s)/year Population and Calendar period Methods Key findings pertinent to heart
failure
Validity and generalizability issues (including
Indigenous identification)




Whole of Australia Indigenous
population (Residents in Very
Remote areas not included in
non-Indigenous NHS
comparator group)
Design: Standardised prevalence ratio of HF
among Indigenous Australians 1.7
(males 1.9; females 1.6)
• Ascertainment of HF based on self-report;
conflated with self-report of oedema.
Cross-sectional survey
Data source: questionnaire of
persons usually resident in
private dwellings
• Comparator non-Indigenous data excluded
subjects in Very Remote areas.




• Low precision of SPR estimate, especially for
males
• Indigenous status according to self-
identification in Census




4. Mortality & survival
Field (2003) [34] SA, Qld, WA, NT population Design: Descriptive study Indigenous HF mortality rates almost
threefold higher than non-Indigenous.
Disproportionately high HF mortality
among Indigenous males aged 55–64
years.
• Rates calculated for population aged ≥45 years
only
Data source: Administrative
data (NMD) • Inter-jurisdictional variation in Indigenous
identification data quality
Period: 1995–96 to 1997–98
and 1998–99 to 2000-01
Outcome: Deaths
• Inherent shortcomings of HF identification on
death certificates
Penm (2008) [33] SA, Qld, WA, NT population Design: Descriptive study Age-adjusted Indigenous HF mortality
rates more than double non-Indigenous
rates.
• Inter-jurisdictional variation in Indigenous
identification data quality
Period: 2002-05 Data source: Administrative
data (NMD)
In 45–64 year age-group, mortality
rate ratio 6.4.
• Inherent shortcomings of HF identification on
death certificates
Outcome: Deaths
























Table 3 Reports (Continued)




GP practices Australia-wide Design: Cross-sectional
survey
Crude proportion of HF encounters
lower among Indigenous (1.0/100, CI
0.6-1.3) than non-Indigenous patients
(0.7, CI 0.7-0.8)
• Data difficult to interpret: not person-based
(cannot identify recurrent attendances for the
same person), estimates conflate differences in
underlying morbidity with differences in service
access and utilisation






Age-standardised proportion of HF
encounters higher for Indigenous
patients (ratio 2.6)
Outcome: Indications for GP
encounters
• No formal basis for Indigenous identification;
patients not providing Indigenous status
conflated with ‘non-Indigenous’
• Imprecise estimates for Indigenous attendances
Beach Survey AIHW
(2011) [36]
GPs Australia-wide Design: Cross-sectional
survey
Crude proportion of HF encounters
lower among Indigenous (0.9/100, CI
0.6-1.2) than non-Indigenous patients
(0.7, CI 0.7-0.7)
• Data difficult to interpret: not person-based
(cannot identify recurrent attendances for the
same person), estimates conflate differences in
underlying morbidity with differences in service
access and utilisation
Period: April 2004-







Age-standardised proportion of HF
encounters higher for Indigenous
patients (ratio 2.6)
Outcome: Indications for GP
encounters
• No formal basis for Indigenous identification;
patients not providing Indigenous status
conflated with ‘non-Indigenous
Imprecise estimates for Indigenous attendances
(b) Hospitalisations
Nichol (1999) [37] Patients admitted to Australian
public and private hospitals
Design: Descriptive study 970 separations with principal
diagnosis HF among indigenous;
39,305 Non-Indigenous
• Separation rate-ratio not provided
Data source: Administrative
data (NHMD)
Crude average length of hospital stay
for ‘congestive heart failure) shorter
for Indigenous than non-Indigenous
patients (6.5 vs 9.4 days)
• Data not person-based: cannot identify
recurrent separations for the same person
Period:July 1995-June 1996 Outcome: Principal diagnosis
reported for hospital
separations
• Indigenous identification varies between
jurisdictions, Indigenous identity likely under-
identified at a single separation




















Table 3 Reports (Continued)
Field (2003) [34] Patients admitted to SA and
NT hospitals only
Design: Descriptive study July 1998-June 2001 triennium: age-
standardised separation rates (HF or
hypertensive heart disease) higher
among Indigenous than non-
Indigenous patients (males: 1555/105
vs 743/105; females: 1579/105 vs
541/105)
• Rates calculated for population aged ≥45 years
only
Data source: Administrative
data (NHMD) • Data not person-based so cannot distinguish
repeat recurrent separations for the same person.
Period: 1995–96 to 1997–98




HF hospitalisation rates fell among
both sexes, in both Indigenous and
non-Indigenous populations, between
1995–98 and 1998–2001 triennia.
• Not nationwide data: SA/NT only.
• Indigenous identity likely under-identified
at a single separation.
AIHW (2008) [35] Patients admitted to private
(excluding NT) and public
hospitals in NSW, Vic, Qld,
WA, SA and NT.
Design: Descriptive study Age-standardised hospital separation
ratio (Indigenous:non-Indigenous) for
HF 3.4.
• Data not person-based: cannot identify
recurrent separations for the same person
Data source: Administrative
data (NHMD)
Average bed days for congestive heart
failure 5.7 (Indigenous patients); 7.7
(non-Indigenous)
• Report restricted to jurisdictions with better
Indigenous identification, however this varies
between included jurisdictions, Indigenous
identity likely under-identified at a single
separation
Period: July 2004 to June 2006 Outcome: Diagnoses reported
for hospital separations
AIHW (2011) [36] Patients admitted to private
(excluding NT) and public
hospitals in NSW, Vic, Qld,
WA, SA and NT.
Design: Descriptive study Age-standardised hospital separation
ratio (Indigenous:non-Indigenous) for
HF 3.0.
• Data not person-based: cannot identify
recurrent separations for the same person
Data source: Administrative
data (NHMD)
Period: July 2006 to June 2008 Outcome: Diagnoses reported
for hospital separations
Average bed days for congestive heart
failure 5.4 (Indigenous patients); 7.5
(non-Indigenous)
• Report restricted to jurisdictions with better
Indigenous identification, however this varies
between included jurisdictions, Indigenous




Patients admitted to private
(excluding NT) and public
hospitals in NSW, Vic, Qld,
WA, SA and NT.
Design: Descriptive study Age-standardised hospital separation
rates for congestive heart failure 6.1
(Indigenous) vs 2.0 (non-Indigenous)
• Data not person-based: cannot identify
recurrent separations for the same person
Data source: Administrative
data (NHMD)
Period: 2008-09 Outcome: Diagnoses reported
for hospital separations
• Indigenous identification varies between
jurisdictions, Indigenous identity likely under-
identified at a single separation
AIHW (2011) [39] Patients admitted to public and
private hospitals in all states
and territories.
Design: Descriptive study Crude hospital separation rates for
congestive heart failure:





• Data not person-based: cannot identify
recurrent separations for the same person
Period: 2008-2009 Outcome: Principal diagnosis
reported for hospital
separations
(Rate ratio: 1.33) • Rates adjusted for Indigenous under-
identification.
























Patients >45 years admitted to
public and private hospitals in
NSW.
Design: Descriptive study 2% of ‘potentially avoidable’ HF
admissions of patients occurred among
patients identified as Aboriginal, with
‘2% of the NSW population’
considered to be Aboriginal.
• Data not person-based: cannot identify
recurrent separations for the same person
Data source: Administrative
data (APDC)




• Crude proportion only
No adjustment for Indigenous under-




Patients >45 years with pre-
existing record of HF
hospitalisation admitted to
public and private hospitals in
NSW.
Design: Cohort study Patients with pre-identified HF
admitted on >1 occasion with HF
during year of study were more likely
to be Aboriginal (3%) than those with





• Proportion of cohort identified as Aboriginal
not stated
No adjustment for Indigenous under-
identificationPeriod: July 2009-June 2010 Outcome: admissions and re-
admissions
8. Health service delivery issues (including needs, access and barriers)
Nil
9. Costs related to HF diagnosis and care
AIHW (2011) [39] Patients admitted to public and
private hospitals in all states
and territories.
Design: Descriptive study For congestive heart failure, patients
identified as Indigenous accounted for
3.9% of total expenditure for this
condition. Expenditure on CHF
hospitalisation per person:
• Data from all states and territories.
Data source: Administrative
data (NHMD)
• Indigenous identification varies between
jurisdictions, Indigenous identity likely under-
identified at a single separation







AIHW: Australian Institute of Health and Welfare.
APDC: Admitted Patient Data Collection (New South Wales).
BEACH: Bettering the Evaluation and Care of Health.
HF: heart failure.
NATSIHS: National Aboriginal and Torres Strait Islander Health Survey.
NHMD: National Hospital Morbidity Database.
NHS: National Health Survey.
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tive patients, HF (35% versus 11%; p=0.013) and cor
pulmonale specifically (19% versus 3%; p=0.023) were
both more common in HTLV-1 seropositive than
HTLV-1 seronegative subjects.
The frequency of HF with preserved ejection fraction was
only addressed in two published studies. In a study of HF
patients identifying as Indigenous referred for echocardio-
graphy in north Queensland [27], the reported proportion
with preserved ejection fraction (57%) was considered to be
‘at the upper end of that expected’ from studies of other
populations. However, the study did not provide non-
Indigenous comparison data. In the Central Australian
study, 61% of those with HF had impaired left ventricular
systolic function (ejection fraction <50%) and 39% had HF
with preserved ejection fraction [25].
Co-morbidities
Despite the known endemicity of chronic diseases such
as diabetes and renal dysfunction among Indigenous
Australians, the only publication which dealt specifi-
cally with co-morbidities for HF per se in an Indige-
nous population was the work of McGrady and
colleagues. They reported the following comorbidities
being significantly more prevalent in HF cases than
non-cases in the Central Australian Aboriginal adult
population: CAD (39%), Diabetes (78%), hypertension
(78%) and ARF/RHD (26%) [25].
Mortality & survival
Peer-reviewed studies
The peer-reviewed literature provided no population-based
data on HF mortality among Indigenous Australians. How-
ever, deaths attributed to HF have been examined in the
context of coronary heart disease and rheumatic heart
disease (RHD). The Central Australian Secondary Preven-
tion of Acute Coronary Syndromes (CASPA) Study was a
retrospective audit of patients hospitalised with ACS in the
Northern Territory [28]. After 2-year follow-up, the crude
frequency of deaths attributed to HF was similar in Indi-
genous and non-Indigenous groups. However, Indigenous
subjects had a substantially lower mean age on admission
(50.1 vs. 59.3 years; p<0.001), despite which they were
significantly more likely than non-Indigenous subjects to
have died from any cause (30.0% vs. 17.8%; p=0.002). In
the previously cited WA cohort of first-ever MI survivors
[24], HF as a co-morbidity was independently associated
with about double the risk of either recurrent AMI admis-
sion or cardiovascular death in Indigenous and non-
Indigenous subjects.
Carapetis et al. [29] examined the outcome of cardiac
valve replacement in subjects with RHD in northern
Australia. In this retrospective chart review with some
prospective follow-up of 80 consecutive patients (70 ofwhom were Indigenous), there were 29 late deaths, inclu-
ding 27 considered consequent to the RHD, 12 of which
were attributed to HF and 1 to ‘pneumonia with HF’. The
ages of the patients at the time of death were not reported.
Government reports
In a report specifically addressing HF, Heart failure. . .what
of the future? [34], the AIHW provided National Mortality
Database (NMD) data from South Australia, Western
Australia, Queensland and the Northern Territory only,
due to poor Indigenous identification in administrative data
in other jurisdictions. Death rates attributed to HF were
reported to have remained ‘fairly static’ between 1995-96/
1997-98 and 1998-99/2000-01 among male and female
Indigenous and non-Indigenous populations. However,
age-standardised death rates (45 years and over) in the
period 1998–99 to 2000–01 where HF or hypertensive
heart disease was certified as the underlying cause were
nearly threefold higher in the Indigenous population (173
per 100,000 males and 160 per 100,000 females) than in the
non-Indigenous population (60 per 100,000 males and 66
per 100,000 females). The study found that there was
disproportionately high mortality among middle-aged Indi-
genous males. Indeed, the death rate among 55–64 year old
males (47 per 100,000) was higher than among 65–74 year
olds (34 per 100,000), although the rate rose markedly in
the Indigenous male population aged 75 years and over.
In a more recently published AIHW report, again based
on NMD data from the same four jurisdictions for the
period 2002–04 [33], age-adjusted mortality attributed to
HF was estimated to be over twice as high in Indigenous as
non-Indigenous Australians overall, and 6.4 times as high
in the 45–64 year age group. The overall standardised HF
mortality ratio was more accentuated for the female (2.4)
than the male Indigenous population (2.0).
Quality of life
There were no studies or reports dealing specifically with
quality of life in HF per se among Indigenous Australians.
Therapeutic interventions
There were no studies or reports dealing specifically
with therapeutic interventions for HF tailored and tar-
geted for Indigenous Australians.
Health service utilisation (including medication
adherence, outpatient attendances, hospitalisations,
cardiac rehabilitation)
Peer-reviewed studies
Thomas et al. examined the conditions accounting for
attendances at a community-controlled Aboriginal
Medical Service in Darwin [31]. HF was managed at
3.4% (CI 1.9-4.9%) of consultations, by an Aboriginal
health worker (AHW) only (42.6%), an AHW together
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non-Indigenous comparison group was examined in
the study. However, the authors noted that in national
data from the Australian Morbidity and Treatment
Survey, HF had been managed at 1.9% of primary care
(i.e., general practice) consultations. Another study
from NSW, reported in a conference abstract, found
that of 68 patients referred to an urban AMS specialist
cardiology clinic, 3% had heart failure [30].
Other reports
Between 1999 and 2011, six government reports were pub-
lished providing data on differences in hospital separation
rates for HF between indigenous and non-Indigenous
people in various Australians jurisdictions. These reports
were based on data derived from the National Hospital
Morbidity Database (NHMD), and were characterised by
separation-based rather than person-based analyses and in-
complete (and varying) coverage of all states and territories
(due to poor quality of data in some jurisdictions).
A Commonwealth Department of Health and Aged
Care report (1999) estimated a total of 970 Indigenous
and 39,305 non-Indigenous public and private hospital
separations in Australia with an ICD-9-CM principal diag-
nosis code for heart failure. Neither crude nor standar-
dised separation rate ratios were provided [37].
The 2003 AIHW report Heart failure. . .what of the
future? analysed NHMD data from South Australia and the
Northern Territory only (the NT providing public hospital
data only) for two time periods, 1995-96/1997-98 and
1998-99/2000-01. Although limited in geographic and age
(45 years and over) coverage, a fall in HF hospitalisation
rates was reported for male and female Indigenous as well
as non-Indigenous populations. In the later triennium, age-
standardised hospitalisation rates where heart failure or
hypertensive heart disease was the principal diagnosis were
1555 per 100,000 for the male Indigenous population (com-
pared with 743 for the male non-Indigenous population)
and 1579 per 100,000 for the female Indigenous population
(compared with 541 per 100,000 in the female non-
Indigenous population). This translates into a standardised
rate ratio of about 2 for men and 3 for women. As with
mortality rates, hospitalisation rates for Indigenous males
were higher in the 55–64 year age group than older age
groups [34].
Australian hospital separations (excluding Tasmania,
ACT and private hospitals in NT) from July 2004 to June
2006 were also reported by the AIHW, by Indigenous
status, for the top 10 ambulatory care sensitive conditions
[35]. For congestive heart failure, age standardised rates
were 6.6 separations per 1000 Indigenous people (95% CI
6.3-6.9), compared with 1.9 per 1000 for ‘Other’ persons,
reflecting a standardised separation ratio of 3.4. Analogous
data were published for the period July 2006 to June 2008.Age standardised rates were 5.9 separations per 1000 Indi-
genous people (95% CI 5.6-6.1), compared with 2.0 per
1000 for ‘Other’ persons (Ratio 3) [36].
More recently, a Productivity Commission report
provided multijurisdictional National Hospital Morbidity
Data on 2008–2009 hospital separations for selected
chronic conditions by Indigenous status [38]. Tasmania,
ACT and private hospitals in the NT did not contribute
data. For congestive heart failure, the rates of separations
per 1000 people, directly standardised using the Australian
2001 standard population, were 6.1 and 2.0 for patients
identified as Indigenous and non-Indigenous respectively.
Additionally, the AIHW published 2008–2009 public and
private hospital separation rates for all states and territories
combined, by Indigenous status, in which the principal
diagnosis was a condition for which hospitalisations are
considered potentially preventable, including congestive
heart failure [39]. The crude rates, adjusted in the original
report for Indigenous under-identification, were 2.8 per
1000 population for Indigenous persons and 2.1 per 1000
for non-Indigenous persons (Crude rate ratio = 1.33).
Despite differences in methodology with respect to age
group inclusion, geographic coverage and diagnostic codes,
these government reports show that Indigenous people in
Australia have about 3 times higher hospitalisation rates
than non-Indigenous people, when the different age distri-
bution is taken into account. Average bed days per HF
admission were lower in Indigenous compared with non-
Indigenous patients [35,37].
The Bureau of Health Information in NSW has recently
published two reports based on administrative data from
that state [40,41]. The first examined patient admissions to
public and private hospitals, and reported that 2% of the
“potentially avoidable” admissions of patients with HF
occurred among Indigenous people, the same as the popu-
lation proportion of Indigenous people in NSW [40]. This
study reported crude proportions only (and thus did not
take into account age differences) and was not person-
based, hence could not identify recurrent admissions of the
same person. The second report linked hospitalisation and
mortality data in a cohort of individuals aged >45 years with
evidence from hospital records of pre-existing HF. Abori-
ginal people were over-represented among those who had
more than one admission with HF during the year of
follow-up: 3% were Aboriginal compared to 2% among
those with one or no HF admissions [41]. While this study
used person-based data, the proportion of the cohort iden-
tified as Aboriginal was not stated, and no adjustment was
made for Indigenous under-identification. Thus, while the
reports overall suggested by crude comparison that poten-
tially avoidable admissions for HF occurred no more
frequently among Indigenous compared with non-
Indigenous people [40], recurrent admissions were more
frequent in Indigenous people [41]. Additionally, the
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proportion of Aboriginal people at risk for HF due to high
rates of IHD and RHD at younger ages.
The only reports covering primary care were the
Bettering the Evaluation and Care of Health (BEACH)
surveys, conducted periodically by the AIHW Australian
General Practice (GP) Statistics and Classification Unit.
These provide data on GP encounters (~1,000 GPs nation-
wide participate annually, with data on 100 consecutive
encounters collected from each). Data from the BEACH
survey on Indigenous HF have been reported in two AIHW
publications. For the BEACH survey years 2002–03 to
2006–07 inclusive, the reported crude proportion of
encounters (number per 100) at which HF issues were
managed by GPs was 1.0 (95% CI 0.6-1.3) for Indigenous
patients vs. 0.7 (95% CI 0.7-0.8) for ‘Other’ patients, with
an age-standardised rate ratio of 2.7 for Indigenous versus
‘Other’ patients [35]. For the overlapping period April
2004-March 2005 to April 2008-March 2009 inclusive, the
reported crude proportion of encounters at which HF
issues were managed by GPs was 0.9 (95% CI 0.6-1.2) for
Indigenous patients vs. 0.7 (95% CI 0.7-0.7) for ‘Other’
patients, with an age-standardised rate ratio of 2.6 for In-
digenous versus ‘Other’ patients [36].Health service delivery issues (including needs, access
and barriers)
In a geo-mapping study of national HF services, Clark et al.
reported lower service provision in rural and remote areas
[32]. The spatial distribution of population, which included
Indigenous status, was derived from Australian Bureau of
Statistics Census data. HF prevalence was not measured
directly but instead derived from European estimates, with
Indigenous prevalence-weighting applied to communities,
based on a combination of census data and AIHW-derived
HF prevalence estimates.
Aspin and colleagues have recently reported findings
from a qualitative study in which patients with chronic
diseases (HF, diabetes and chronic obstructive pulmonary
disease) were interviewed about the barriers and facilitators
of access to health care and support [42]. Participants
were recruited from Aboriginal Medical Services.
Eleven of the 19 people interviewed had HF, with or
without the other conditions. Those with HF were not
distinguished from those with other chronic diseases,
but issues were considered to be common across all
the diseases. The culturally inappropriate services,
racism, poor communication with health professionals
and financial barriers were all impediments to service
access, whereas support from family, the strength
drawn from the Aboriginal community and regular ac-
cess to good primary health care were regarded as
assisting with participation in care.Costs related to HF diagnosis and care
No peer-reviewed studies were identified on the absolute
or relative costs of HF management among Indigenous
Australians. In 2011, the AIHW published expenditure
estimates based on National Hospital Morbidity Data on
potentially preventable hospital separations, by Indigenous
status, for both public and private hospitals in all states
and territories during the period 2008–09. Patients identi-
fied as Indigenous accounted for 3.9% of the expenditure
for HF overall ($14.5 million from a total of $372.8 million
for all patients). This corresponded with a calculated
approximate expenditure on HF hospitalisation of $26.70
per Indigenous person, compared with $16.90 per non-
Indigenous person (crude Indigenous to non-Indigenous
expenditure ratio =1.58) [39]. In the analysis, a loading of
5% was added to the Indigenous patient costs to account
for previously estimated excesses in comorbidity for simi-
lar Diagnosis Related Groups.Discussion
This comprehensive review of HF among Indigenous
Australians reveals substantial current knowledge gaps that
potentially hinder health service planning. Peer-reviewed
journal papers as well as other publications sourced from
administrative data were considered for inclusion, which
was determined by relevance to a range of pre-defined sub-
headings under the broad rubric of HF.
Priority was given to peer-reviewed articles. An exhaus-
tive, multiple-database keyword search strategy was used
for the journal literature, maximising the sensitivity of cit-
ation retrieval. However, most papers identified were either
not principally concerned with HF and/or provided local
data with questionable generalisability. Despite abundant
published research on the likely major antecedents of HF in
this population (coronary disease, hypertension and rheu-
matic heart disease), few articles included explicit mention
of HF, an essential inclusion criterion.
The search of applicable Australian government websites
as well as the Google interface identified a number of
reports that provided data comparing Indigenous with non-
Indigenous populations; these dominated the publications
identified. Web searches of this type are inherently less sys-
tematic than those of journal databases, and some grey
literature may have been overlooked. The validity of go-
vernment reports is compromised by the quality of admin-
istrative data with respect to ascertainment of HF, the
accuracy of which varies depending on the indicator being
measured [43,44] and by shortcomings in the identification
of Indigenous status. Additionally, these data capture only
hospitalisations and deaths, not the less severe end of the
illness spectrum [45,46]. Despite these limitations, the indi-
cators show substantial disparities in the occurrence of HF
between Indigenous and non-Indigenous populations.
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prevalence of HF among Indigenous Australians identified
in our search was derived from the 2004–05 NATSIHS sur-
vey [33]. An age-standardised prevalence of HF 1.7 times
higher among Indigenous than non-Indigenous Australians
was reported, but the precision of estimates (judging by
wide confidence intervals) was poor, particularly for Indi-
genous males. Although the ABS made substantial efforts
to optimise Indigenous participation and the accuracy of
self-report in the survey, the latter was compromised by the
potential for differential ascertainment of HF from Indige-
nous and non-Indigenous subjects and the conflation of
non-specific ‘oedema’ with HF. The recent cross-sectional
population-based study in several Central Australian
communities, incorporating comprehensive cardiovascular
assessment [25], detected HF in 5.3% (95%CI 3.2-7.5%) of
study participants, with only 35% of these having a pre-
existing diagnosis of this condition. Although interpre-
tability is limited by the absence of a non-Indigenous
comparison group and by uncertainty regarding the rep-
resentativeness of the participants, making it difficult to
compare with whole-population data from the NATSIHS
survey [33], there appears to be considerable under-diagno-
sis, at least in remote areas. The high proportion of newly
detected cases in a young population (mean age 44 years
[SD14]) raises the possibility of a ‘large, as yet unidentified,
burden of HF in the [broader] Australian Aboriginal
population’ [25].
The higher prevalence of HF in Indigenous people is also
seen in clinical populations, with two retrospective cohort
studies in which HF was a significantly more common
current or previously documented co-morbidity in Indige-
nous compared to non-Indigenous patients hospitalised for
myocardial infarction [23,24]. Death data in government
reports are an important although problematic source of
information about HF among both Aboriginal and non-
Aboriginal people. The AIHW publications with multi-
jurisdictional mortality data report death rates due to HF
in the Indigenous population as double to treble those of
non-Indigenous Australians, with the ratio higher for the
middle aged. However, analysis of deaths attributed to HF
is inherently problematic, particularly from administrative
data. It has been argued that HF is a mode rather than
a cause of death, that it is inconsistently recorded in
death certification, and that the redistribution from HF
codes to other causes in death coding is poorly stan-
dardised to the underlying aetiology [47]. Indeed,
deaths reported as HF-related in administrative data
have been considered as constituting ‘garbage’ codes
that obscure the epidemiology of underlying causes of
cardiovascular mortality [43]. It is also unknown to
what extent comparative mortality rates have been
miscalculated because of misclassification of Indige-
nous status, although linked data studies indicate thatIndigenous all-cause mortality rates are underesti-
mated [48].
In the literature reviewed, HF was frequently mentioned
in passing as a subsidiary endpoint or as a covariate in
analysis without further elaboration or interrogation. Not
unexpectedly, HF was often a concomitant or complication
of coronary disease [23,24,28], rheumatic heart disease [29],
and, in one report, chronic airway disease (bronchiectasis)
[26]. Finding that the proportion of Indigenous HF in
which ejection fraction is maintained was at the upper limit
of that expected from studies of other populations [27] is
consistent with a high prevalence of coronary and hyper-
tensive heart disease and ‘diabesity’ in this population [5].
However, no studies were identified that specifically
provided data on the distribution of underlying causes of
HF in the Indigenous population nationwide, although the
most recent Australian and Indigenous Burden of Disease
reports describe the use of (unpublished) estimates from
hospital data to redistribute the burden of HF to underlying
causes [45,49]. Heart failure in a Central Australian
adult Aboriginal population sample was strongly associated
with well-recognised risk factors (most especially coronary
disease, diabetes mellitus, hypertension, obesity and rheu-
matic heart disease or history of rheumatic fever) [25].
Consistent with international evidence [50], HF is a pre-
dictor of increased morbidity and mortality following myo-
cardial infarction in both Indigenous and non-Indigenous
Australians [24]. Nonetheless, there are no longitudinal
follow-up data quantifying or examining the determinants
of morbidity, quality of life, survival or mortality among
Indigenous Australians with established HF. Given the ra-
ther bleak natural history of HF regardless of cause [15]
and the known efficacy of timely interventions [16,17],
optimal tertiary prevention tailored to the needs of the
Indigenous HF population is likely to be useful in impro-
ving Indigenous outcomes.
The three-fold excess frequency of HF-related hospitali-
sations reported by AIHW for Indigenous Australians
parallels the estimated disparity in death rates. Administra-
tive data on hospitalisation are widely used for information
about chronic illnesses such as HF, but are influenced by
factors such as access to and quality of ambulatory care as
well as underlying disease prevalence and severity [51].
Further limitations include the inter-jurisdictional variation
in quality of Indigenous identification [35,36], the short-
comings of HF ascertainment from disease codes [18,44],
and their inability to capture information on disease
frequency in the community. In metropolitan settings, a
HF-related code in administrative data indicates a clinically
verifiable diagnosis of HF with a positive predictive value of
>90% [46]. However, it is unknown to what extent this
validation is applicable to rural and remote settings where
access to specialist expertise and diagnostic technology is
more limited and the proportion of Indigenous patients is
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trative records can be very poor, even in urban teaching
hospitals [18].
No report identified for this review combined both age-
standardised analysis and investigation of Indigenous iden-
tification, both of which are critical for interpretability. One
report comparing Indigenous and non-Indigenous hospita-
lisations for HF excluded persons <45 years, the age range
in which disparities appear to be the greatest [34]. The
markedly lower hospitalisation rate ratio in crude data
(1.33) compared to about 3 in age-standardised compari-
sons [39] highlights the differing age distributions of
the populations and the early age of HF onset in the Abori-
ginal population. Meaningful comparison of Indigenous
and non-Indigenous HF-related hospitalisations requires
inclusion of adults across a wider age range. There is an
interaction of Aboriginality with age, therefore a single age-
standardised rate over all adult ages will obscure variation
in disparities across the lifespan. This can be addressed by
comparing age-standardised rates separately for younger
and older age groups as has been done in a study of Indi-
genous incidence rates for myocardial infarction [52].
The listing by AIHW of HF as among ‘preventable’ causes
of hospitalisation highlights the role of primary care in pre-
venting hospital admissions [51]. Only one peer-reviewed
article reported general practice attendances by Indigenous
Australians for HF management, based on attendances at a
Darwin AMS [31], and one conference abstract reported
attendances at a cardiology clinic within an AMS in Sydney
[30]. Neither study included local non-Indigenous compa-
rison data. Their generalisability to Indigenous populations
elsewhere is also uncertain. The BEACH survey showed an
age-standardised proportion of GP visits for HF as 2.6-fold
higher among Indigenous than ‘Other’ attendees. However,
a sub-study in which Indigenous identification was specifi-
cally explored suggested considerable Indigenous under-
identification with 2.2% of patients in the sub-study identi-
fied as Indigenous, compared with 1.4% in the main survey
[36]. Furthermore, it is difficult to interpret data on
condition-specific proportions of health encounters
such as primary care attendances, as they are not indi-
vidual patient-based and depend on both the frequency
of encounters for other conditions and variation in the
condition-specific expertise offered by different provi-
ders. Between-population comparisons of such propor-
tions are thus confounded by other morbidities, and
cannot be taken at face value as indicators of disease
frequency or disease-specific health behaviour.
As cardiovascular disease is largely preventable and
linked to social determinants of health, these should be an
important focus for health care interventions. Access to
health care is an important moderator for health outcomes.
Accordingly, in addition to epidemiological indicators,
affordability, cultural appropriateness and geographicalaccess to health services need to be investigated. Although
the complex needs and many barriers that Indigenous
people experience in accessing health services are well
documented [28,53,54], only one publication was identified
that had a strong focus on HF in this regard [42]. Late pre-
sentation is cited as a contributor to poor health outcomes
for Indigenous Australians, such as in the setting of acute
coronary syndrome [55], but there are no published data
for this population on delayed in presentation in HF speci-
fically. The work of Aspin and colleagues [42] accords with
the barriers and inequities already described for ACS,
cancer, renal and mental health. Common themes include
negative associations with hospitals as a result of death of
relatives, racism and cultural alienation; social, economic
and cultural barriers; and competing priorities [56,57].
However, given the complexity of HF, further research
could usefully identify specific HF-related issues in order to
optimise its culturally appropriate management, including
palliative care, in this population.
The overall lack of data on HF therapeutics in the Indi-
genous population is also noteworthy. Management inter-
ventions for HF often entail complexity that is particularly
challenging for individuals in disadvantaged and remote
communities. For example, chronic anticoagulation is prob-
lematic, given the requirement for rigorous monitoring to
avoid potentially life-threatening adverse effects [58]. Dis-
ease management is impacted by the disproportionate
burden of co-morbidities that accompanies HF in this
population, with co-existing conditions being impor-
tant determinants of quality of life, the complexity of
medical interventions, and survival. Furthermore,
biological differences between population groups in
response to HF therapies have been noted in other
settings [59]. This issue remains unexplored for the
Australian Indigenous population.
Conclusions
The poor health outcomes experienced by Indigenous
Australians can be attributed to socio-economic disadvan-
tage and marginalisation and are manifest in a range of
chronic conditions that include cardiovascular diseases
[60]. Heart failure, a disabling and survival-limiting ‘down-
stream’ complication of these conditions, presents sub-
stantial challenges in its own right. Although this
systematic review demonstrates that high-quality data are
limited, better information is beginning to emerge,
bolstering the evidence that Indigenous Australians have
an excess burden of heart failure in comparison with their
non-Indigenous counterparts.
Clearly, optimising the delivery of preventive and thera-
peutic interventions for HF in Indigenous Australians is
predicated on a sound knowledge of the underlying causes
and comorbidity burden. The likely antecedents and conco-
mitants of HF in this population are well described: all
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disease, chronic kidney disease, metabolic syndrome and
diabetes are known to be prevalent in substantial excess
[6,7,10]. The substantial proportion of HF cases with pre-
served ejection fraction documented in North Queensland
[27] and Central Australia [25] is consistent with this
aetiological spectrum. Additionally, the prevalence of
rheumatic valvular disease is extremely high among
certain Indigenous populations, namely those in Northern
Australia [61]. However, the role of these conditions in the
pathogenesis of HF in Indigenous Australians has only been
specifically examined in a single Central Australian study
and its generalisability to the broader Australian context is
uncertain [25]. The aetiological contribution of these risk
factors to the burden of HF in the greater Australian
Aboriginal population has not been formally quantified and
constitutes an important gap in current knowledge.
Accurate data on indicators of HF among Indigenous
Australians, as well as information on their access to and
utilisation of health services for this problem, could inform
better care and policy development but are limited by the
scarcity of quality information identified in this review.
Considering the constraints on administrative data, high-
quality research is required to confirm epidemiological indi-
cators of HF and to monitor trends adequately. Such data
are now beginning to emerge [25] and reflect growing
recognition of the huge health disparities in Indigenous
Australians and commitment to Closing the Gap. The
Australian Bureau of Statistics has publicised that the next
NATSIHS will be the largest Aboriginal and Torres Strait
Islander health survey to date and ‘will expand on the
2004–05 survey by increasing the number of participants
by 30%, collecting new information on exercise, diet
(including bush foods) and measures of cholesterol, blood
glucose and iron. For the first time, the ABS will directly
measure obesity and blood pressure levels, as well as nutri-
tional status and chronic disease’ [62]. In view of the diver-
sity of Indigenous populations and known geographical
inequities in health service provision, local as well as whole
or multi-jurisdictional epidemiological studies are desirable.
In addition, qualitative investigations of the impact of HF
and effective, culturally suitable approaches to HF manage-
ment in Indigenous Australians are needed.
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